[S-29] Symposium 29
Preparing for disease-modifying therapies in PD – From biomarkers, animal models to novel therapeutic approach

[S-29-2] Updates of liquid biomarkers and disease-modifying potential of an antiparkinsonian drug in PD

^○Shigeki Arawaka (Department of Internal Medicine IV, Division of Neurology, Osaka Medical College, Japan)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

Education:
1996 Ph.D. Yamagata University Graduate School of Medicine
1991 M.D. Yamagata University School of Medicine

Academic Positions:
2017-present Professor, Department of Internal Medicine IV, Osaka Medical College
2016-2017 Associate Professor, Department of Neurology, Hematology, Metabolism and
Diabetology, Yamagata University Faculty of Medicine
2010-2016 Assistant Professor, Department of Neurology, Hematology, Metabolism and
Diabetology, Yamagata University Faculty of Medicine
1999-2002 Postdoctoral fellow, Centre for Research in Neurodegenerative Diseases,
University of Toronto (Prof. St. Geroge-Hyslop lab.)
1998-1999 Postdoctoral fellow, Department of Neuroscience, Osaka City University
Medical School (Prof. H. Mori lab.)
1997-1998 Postdoctoral fellow, Department of Molecular Biology, Tokyo Institute of Psychiatry
(Dr. H. Mori lab.)